English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 July 2022, 09:17 HKT/SGT
Share:
    

Source: Apollomics, Inc.
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

Foster City, CA, and Hangzhou, China, July 26, 2022 - (ACN Newswire) - Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer.

"We are very excited to have Jane join our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "Jane is a drug discovery expert in a number of therapeutic areas, including oncology, with a proven track record advancing compounds from the laboratory to clinical development. With her broad experience, she will make significant contributions to our global research strategy."

"I am pleased to join a Company dedicated to the discovery, research, and clinical development of novel agents targeting multiple oncology indications. I look forward to growing our global team to discover and advance new compounds into the clinic," added Jane Wang, Ph.D., Chief Scientific Officer.

Dr. Wang brings over 20 years of drug discovery experience in the biopharmaceutical industry. Most recently, she served as Vice President, Medicinal Chemistry at WuXi AppTec where she worked to enhance RNA drug discovery and led multiple teams in medicinal chemistry and synthetic organic chemistry. Prior to WuXi, Dr. Wang spent 12 years on the drug discovery team at Pfizer, Inc. as a senior principal scientist, focusing on diseases in oncology, inflammation, and the central nervous system Previously, she did her postdoc at the U.S. National Institute of Health and at Schering-Plough. Dr. Wang earned a Ph.D. from the University of Maryland Baltimore County and a B.S. in Applied Chemistry from Fudan University. She is an inventor/co-inventor of over 50 patent applications and an author of over 35 publications.

About Apollomics Inc.

Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including a novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.

Contact Information:

Investor Contact:
Raymond Low
VP Finance, Corporate Controller
(925) 451-0712
Raymond.Low@apollomicsinc.com

U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com

China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com

Topic: Press release summary
Source: Apollomics, Inc.

Sectors: BioTech, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Apollomics, Inc. Related News
Jan 3, 2024 20:10 HKT/SGT
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组
Jan 3, 2024 20:09 HKT/SGT
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組
Mar 30, 2023 20:31 HKT/SGT
冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市
Mar 30, 2023 20:30 HKT/SGT
冠科美博(Apollomics Inc.)宣佈完成和SPAC Maxpro合併,並在納斯達克上市
Mar 30, 2023 20:29 HKT/SGT
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575